Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | DRD5 | P21918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24122147 | 1.00 | SIGMAR1 (0.58) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL22549343 | 0.90 | ACHE (0.62) | SIGMAR1KDM4E | |
| SCHEMBL17517486 | 0.82 | SIGMAR1 (0.68) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL7783645 | 0.80 | DRD1 (0.62) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL6369610 | 0.79 | HTR1A (0.71) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10396301 | 0.79 | DRD1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL1415530 | 0.77 | HTR1A (0.81) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL10397222 | 0.76 | SIGMAR1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL30443405 | 0.76 | SIGMAR1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A | |
| SCHEMBL14656766 | 0.76 | SIGMAR1 (0.61) | SIGMAR1HTR1AKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621675-B | Tricyclic compounds useful for the treatment of proliferative diseases | 阿古诺治疗有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021254493-A1 | CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | PRMT5, HDAC5, CDK15 | SIGMAR1 3868/4885HTR1A 3202/4885KDM4E 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.